Literature DB >> 23307488

Anti-inflammatory effect of exercise, via reduced leptin levels, in obese women with Down syndrome.

Francisco J Ordoñez1, Gabriel Fornieles-Gonzalez, Alejandra Camacho, Miguel A Rosety, Ignacio Rosety, Antonio J Diaz, Manuel Rosety-Rodriguez.   

Abstract

Recent studies have reported that obese young people with Down syndrome suffer from low-grade systemic inflammation. Whereas this condition may be improved in the general population by regular exercise, the problem has received no attention in the case of people with intellectual disability. Therefore, the authors' aim was to assess the influence of aerobic training on plasma adipokines in obese women with Down syndrome. Twenty obese young women with Down syndrome volunteered for this study, 11 of whom were randomly assigned to a 10-wk aerobic-training program. They attended 3 sessions/wk, which consisted of warm-up exercises followed by the main activity on a treadmill (30-40 min) at a work intensity of 55-65% of peak heart rate and ended with a cooling-down period. The control group included 9 women with Down syndrome matched for age, sex, and body-mass index. Fat-mass percentage and distribution were measured, and plasma adipokine levels (leptin and adiponectin) were assessed. In addition, each participant performed a maximal graded continuous treadmill exercise test. These parameters were assessed pre- and postintervention. Aerobic training produced a significant increase in participants' maximal oxygen uptake (20.2 ± 5.8 vs.23.7 ± 6.3 ml · kg-1 · min-1; p < .001), and plasma leptin levels were significantly reduced in the intervention group (54.2 ± 6.7 vs.45.7 ± 6.1 ng/ml; p = .026). Further significant correlations between plasma leptin and indices of obesity were found. In contrast, no significant changes were found in adiponectin levels (p > .05). None of the tested parameters changed in the control group. In conclusion, a 10-week training program reduced leptin levels in obese young women with Down syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23307488

Source DB:  PubMed          Journal:  Int J Sport Nutr Exerc Metab        ISSN: 1526-484X            Impact factor:   4.599


  6 in total

1.  Comparison of the effects of aerobic conditioning before and after pulmonary allergic inflammation.

Authors:  Ronaldo Aparecido da Silva; Francine Maria Almeida; Clarice Rosa Olivo; Beatriz Mangueira Saraiva-Romanholo; Adenir Perini; Milton Arruda Martins; Celso Ricardo Fernandes Carvalho
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

2.  Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials.

Authors:  Zinnat Hasina; Chi Chiu Wang
Journal:  Front Med (Lausanne)       Date:  2022-07-05

Review 3.  The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise.

Authors:  S Schmidt; J M Monk; L E Robinson; M Mourtzakis
Journal:  Obes Rev       Date:  2015-04-15       Impact factor: 9.213

Review 4.  Effects of exercise training on obesity-related parameters in people with intellectual disabilities: systematic review and meta-analysis.

Authors:  J Salse-Batán; M A Sanchez-Lastra; D Suárez-Iglesias; C Ayán Pérez
Journal:  J Intellect Disabil Res       Date:  2022-03-16

Review 5.  Resistance training and Down Syndrome: A narrative review on considerations for exercise prescription and safety.

Authors:  Geiziane Leite Rodrigues Melo; Ivo Vieira de Sousa Neto; Eduardo Fernandes da Fonseca; Whitley Stone; Dahan da Cunha Nascimento
Journal:  Front Physiol       Date:  2022-09-27       Impact factor: 4.755

6.  Resistance circuit training reduced inflammatory cytokines in a cohort of male adults with Down syndrome.

Authors:  Manuel Rosety-Rodriguez; Alejandra Camacho; Ignacio Rosety; Gabriel Fornieles; Miguel A Rosety; Antonio J Diaz; Manuel Rosety; Francisco J Ordonez
Journal:  Med Sci Monit       Date:  2013-11-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.